Affinity Asset Advisors, LLC Inozyme Pharma, Inc. Transaction History
Affinity Asset Advisors, LLC
- $896 Million
- Q1 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 3,867,710 shares of INZY stock, worth $15.5 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
3,867,710
Previous 3,972,318
2.63%
Holding current value
$15.5 Million
Previous $11 Million
68.02%
% of portfolio
0.39%
Previous 1.97%
Shares
9 transactions
Others Institutions Holding INZY
# of Institutions
84Shares Held
47.5MCall Options Held
13.8KPut Options Held
1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$20.6 Million0.01% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million5.72% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million0.29% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.45MShares$13.8 Million0.19% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...